Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03600805

Recruitment Status : Terminated (Protracted recruitment timeline exacerbated by COVID-19 pandemic)

First Posted : July 26, 2018

Last Update Posted : December 28, 2020

Sponsor:

Collaborator:

Regeneron Pharmaceuticals

Information provided by (Responsible Party):

Sanofi

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	November 24, 2020
Actual Study Completion Date :	November 24, 2020

To Top